Medicare Puts Digital Therapeutics on the Fee Schedule – and Adds ADHD for 2026

For most of the last decade, a "mental health app" was something a patient found in an app store – you could not prescribe it, monitor it, or bill for it. Medicare's 2026 rule quietly moves that category. A digital therapeutic is now a regulated, FDA-gated device with a standing place on the fee schedule, and for the first time the pathway reaches ADHD.

What CMS finalized

Since January 2025, Medicare has paid for "digital mental health treatment" through three codes: G0552 for supplying the device and onboarding the patient, and G0553 and G0554 for the monthly clinical work of reviewing data and adjusting the plan. The limit was narrow eligibility – only devices classified as computerized behavioral therapy for psychiatric disorders (21 CFR 882.5801) qualified.

The CY2026 final rule, issued October 31, 2025 and effective January 1, 2026, widens the door to FDA-authorized digital therapy devices for ADHD (21 CFR 882.5803). The bar is deliberately high: a product must clear the FDA's 510(k) or De Novo route and satisfy "special controls" that require its therapeutic model to be validated with clinical data. The device is an adjunct, not a substitute – a clinician stays in the loop, the patient must carry a diagnosed condition, and the billing clinician need not be the diagnostician.

CMS then signalled where this is heading. It asked for public comment on applying the same logic to digital therapeutics for insomnia within psychiatric illness (882.5705), fibromyalgia (882.5804), and gastrointestinal conditions (876.5960). Alongside the device codes, three new add-on codes let primary care practices layer Collaborative Care and Behavioral Health Integration onto Advanced Primary Care Management – another route by which behavioral care enters the reimbursement mainstream.

What it means for your practice

The signal matters more than the dollars. The largest public payer for the oldest US patient population has decided that software, when it carries FDA validation, is a billable clinical tool rather than wellness content. That reframes the question every clinician faces: not "is there an app for this?" but "is there a validated, prescribable one, and who supervises it?"

The friction is equally real. CMS still sets no national price for the device itself under G0552, handing that to regional Medicare contractors through an opaque process, and the billing practitioner fronts the cost – which is why claims volumes have stayed thin. Even so, Medicare's decision sets a reimbursement precedent that commercial coverage has historically tended to follow over time. For clinicians outside the US, the through-line is the reimbursement architecture, not the American billing codes: the modality that gets paid is the one with a regulatory dossier and outcome data, not the one with the best interface.

If you already recommend digital tools, start distinguishing FDA-authorized therapeutics from consumer wellness apps in your notes and referrals. That line is now the one payers draw, and it will increasingly define what you can integrate, monitor, and be reimbursed for.